This instillable system delivers drugs in the eye, improving healing while suggesting better patient compliance.
This instillable in situ gelling drug delivery system bridges laboratory innovation with clinical application by providing a sustained-release platform that simultaneously addresses inflammation and infection, offering a convenient once-daily regimen compared with the frequent instillation required by conventional eye drops that may improve patient compliance.
No takes yet. Share an insight, caveat, or question.
Aghamirsalim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: